PLAY PODCASTS
BioSpace

BioSpace

BioSpace

242 episodesEN

Show overview

BioSpace has been publishing since 2023, and across the 3 years since has built a catalogue of 242 episodes. That works out to roughly 80 hours of audio in total. Releases follow a several-times-a-week cadence.

Episodes typically run ten to twenty minutes — most land between 15 min and 23 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.

The show is actively publishing — the most recent episode landed 4 days ago, with 54 episodes already out so far this year. The busiest year was 2025, with 92 episodes published.

Episodes
242
Running
2023–2026 · 3y
Median length
19 min
Cadence
Several per week

From the publisher

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Latest Episodes

View all 242 episodes

The Golden Triangle and the gaps: Rethinking UK biotech

Jun 25, 202619 min

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Jun 24, 202621 min

From fragile skin to living medicine: Lessons from RDEB

Jun 18, 202621 min

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Jun 17, 202625 min

Portugal, Spain and the new biotech frontier

Jun 10, 202620 min

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Jun 10, 202625 min

Rethinking hair loss treatment

Jun 3, 202621 min

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

Jun 3, 202627 min

France’s biotech ecosystem: science, capital and scale

May 28, 202621 min

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

May 27, 202624 min

Inside Germany’s biotech capital infrastructure and innovation engine

May 21, 202623 min

FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

May 20, 202626 min

From MSCs to iPSCs: building the cell therapy future

May 14, 202620 min

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

May 13, 202615 min

Fibrosis, IPF and the search for better therapies

May 7, 202618 min

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

May 6, 202622 min

What makes life science angel investment work?

Apr 30, 202621 min

Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions

Apr 29, 202622 min

The next era of diabetes management

Apr 23, 202621 min

Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win

Apr 22, 202626 min
2026 BioSpace